IRIS
BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.850
AS - Asia 2.170
EU - Europa 1.419
SA - Sud America 555
AF - Africa 149
OC - Oceania 2
Totale 8.145
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.770
SG - Singapore 710
BR - Brasile 453
VN - Vietnam 438
RU - Federazione Russa 433
HK - Hong Kong 358
CN - Cina 335
IE - Irlanda 274
SE - Svezia 165
FR - Francia 129
IT - Italia 126
GB - Regno Unito 96
IN - India 68
CI - Costa d'Avorio 65
DE - Germania 58
BD - Bangladesh 46
IQ - Iraq 35
MX - Messico 34
AR - Argentina 32
FI - Finlandia 30
ZA - Sudafrica 29
CA - Canada 27
TR - Turchia 23
JP - Giappone 21
NL - Olanda 19
PK - Pakistan 19
PL - Polonia 19
UZ - Uzbekistan 19
CO - Colombia 17
UA - Ucraina 17
VE - Venezuela 17
AT - Austria 16
EC - Ecuador 14
MA - Marocco 14
DZ - Algeria 13
ID - Indonesia 13
AE - Emirati Arabi Uniti 11
JO - Giordania 9
CL - Cile 8
ES - Italia 8
SA - Arabia Saudita 8
TN - Tunisia 8
KE - Kenya 7
MY - Malesia 7
PH - Filippine 7
LT - Lituania 6
IL - Israele 5
KG - Kirghizistan 5
NP - Nepal 5
PY - Paraguay 5
TH - Thailandia 5
AZ - Azerbaigian 4
BO - Bolivia 4
KR - Corea 4
KZ - Kazakistan 4
NG - Nigeria 4
SV - El Salvador 4
BE - Belgio 3
HN - Honduras 3
NI - Nicaragua 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
CR - Costa Rica 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
JM - Giamaica 2
LK - Sri Lanka 2
PE - Perù 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AU - Australia 1
BF - Burkina Faso 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HR - Croazia 1
IR - Iran 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
SI - Slovenia 1
Totale 8.145
Salva come PNG Salva come JPEG
Città #
Ashburn 1.222
Singapore 445
Hong Kong 351
Chandler 297
Dublin 273
San Jose 265
Dallas 175
Boardman 158
Ho Chi Minh City 147
The Dalles 126
Fairfield 123
Hanoi 108
Lauterbourg 104
Lawrence 104
Princeton 104
Beijing 95
New York 82
Moscow 76
Abidjan 65
Los Angeles 64
San Diego 59
Washington 53
Council Bluffs 52
Des Moines 49
São Paulo 47
London 32
Seattle 32
Munich 26
Da Nang 25
Turin 24
Santa Clara 23
Redmond 21
Houston 20
Chennai 19
Tokyo 19
Chicago 18
Columbus 18
Haiphong 18
Rio de Janeiro 18
Tashkent 18
Johannesburg 15
Orem 15
Turku 15
Baghdad 14
Frankfurt am Main 14
Shanghai 13
Amsterdam 12
Boston 12
Brooklyn 12
Hefei 12
Helsinki 12
Montreal 12
Warsaw 12
Brasília 11
Guangzhou 11
Pune 11
Vienna 11
Belo Horizonte 10
Mexico City 10
Salt Lake City 10
Ancona 9
Cambridge 9
Manchester 9
San Francisco 9
Woodbridge 9
Nuremberg 8
Phoenix 8
Ribeirão Preto 8
Atlanta 7
Biên Hòa 7
Elk Grove Village 7
Fortaleza 7
Jakarta 7
Mumbai 7
Nha Trang 7
Poplar 7
Porto Alegre 7
Amman 6
Ankara 6
Denver 6
Dhaka 6
Karachi 6
Nairobi 6
Recife 6
Salvador 6
Thái Bình 6
Bishkek 5
Buffalo 5
Campinas 5
Can Tho 5
Contagem 5
Curitiba 5
Detroit 5
Guayaquil 5
Jeddah 5
Maceió 5
Marche 5
Quito 5
Sterling 5
Wilmington 5
Totale 5.475
Salva come PNG Salva come JPEG
Nome #
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 136
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 121
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 119
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 112
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 111
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 106
The application of cancer stem cell model in malignant mesothelioma 104
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 103
Cancer and the microbiome: Potential applications as new tumor biomarker 101
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 101
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 101
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 100
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 98
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 98
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 96
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 94
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 93
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 93
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 93
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 92
Sorafenib for the treatment of breast cancer 92
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 91
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 91
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 91
VIPoma and PPoma 89
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 89
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 89
Bortezomib: A new pro-apoptotic agent in cancer treatment 87
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 86
New generation anaplastic lymphoma kinase inhibitors 86
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 85
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 85
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 85
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 84
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 84
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 84
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 84
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 83
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 83
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 82
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 82
Germline copy number variation in the YTHDC2 gene: Does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 81
A headlight on liquid biopsies: a challenging tool for breast cancer management 80
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 79
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 79
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 76
How much of familial breast cancer risk is currently explained by the known genes? 75
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 73
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 73
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 73
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 71
The role of targeted therapy for gastrointestinal tumors 71
Fully human antibodies for malignant pleural mesothelioma targeting 71
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 70
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 70
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 70
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 69
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 69
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 68
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 68
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 68
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 67
Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy 66
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 66
Monoclonal antibodies in gastrointestinal cancers 65
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 64
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 64
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 63
Dietary restriction: could it be considered as speed bump on tumor progression road? 62
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 62
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 61
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 61
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 61
Anti-endothelin drugs in solid tumors 60
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 58
EGFR genomic alterations in cancer: prognostic and predictive values 58
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 58
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 58
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 58
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 57
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 57
Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach? 56
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 56
Well-being among Italian medical oncologists: An exploratory study 56
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 56
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 55
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 55
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 55
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 55
Ramucirumab and its use in gastric cancer treatment 54
Multisciplinary management of patients with liver metastasis from colorectal cancer 54
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 54
Sex steroids, carcinogenesis, and cancer progression 54
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 53
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 52
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 52
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 51
HER2-positive male breast cancer: An update 51
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 51
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 51
Totale 7.585
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.708
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.708
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 0 0 0 0 0 0 0 237 13 153 112
2022/20231.116 106 67 91 59 78 196 2 55 343 5 81 33
2023/2024846 157 17 79 122 158 185 18 27 0 9 20 54
2024/20251.794 91 176 29 43 59 138 238 87 472 103 148 210
2025/20264.082 264 227 182 290 479 319 923 507 488 403 0 0
Totale 8.353